Expert consensus on clinical application of 177Lu-prostate specific membrane antigen radio-ligand therapy in prostate cancer
- VernacularTitle:177Lu-前列腺特异性膜抗原放射性配体疗法治疗前列腺癌临床应用专家共识
- Author:
Guobing LIU
1
,
2
;
Weihai ZHUO
;
Yushen GU
;
Zhi YANG
;
Yue CHEN
;
Wei FAN
;
Jianming GUO
;
Jian TAN
;
Xiaohua ZHU
;
Li HUO
;
Xiaoli LAN
;
Biao LI
;
Weibing MIAO
;
Shaoli SONG
;
Hao XU
;
Rong TIAN
;
Quanyong LUO
;
Feng WANG
;
Xuemei WANG
;
Aimin YANG
;
Dong DAI
;
Zhiyong DENG
;
Jinhua ZHAO
;
Xiaoliang CHEN
;
Yan FAN
;
Zairong GAO
;
Xingmin HAN
;
Ningyi JIANG
;
Anren KUANG
;
Yansong LIN
;
Fugeng LIU
;
Cen LOU
;
Xinhui SU
;
Lijun TANG
;
Hui WANG
;
Xinlu WANG
;
Fuzhou YANG
;
Hui YANG
;
Xinming ZHAO
;
Bo YANG
;
Xiaodong HUANG
;
Jiliang CHEN
;
Sijin LI
;
Jing WANG
;
Yaming LI
;
Hongcheng SHI
Author Information
- Keywords: 177Lu-prostate specific membrane antigen; prostate cancer; radio-ligand therapy; expert consensus
- From: Chinese Journal of Clinical Medicine 2024;31(5):844-850,封3
- CountryChina
- Language:Chinese
- Abstract: 177Lu-prostate specific membrane antigen(PSMA)radio-ligand therapy has been approved abroad for advanced prostate cancer and has been in several clinical trials in China.Based on domestic clinical practice and experimental data and referred to international experience and viewpoints,the expert group forms a consensus on the clinical application of 177Lu-PSMA radio-ligand therapy in prostate cancer to guide clinical practice.
